Overview

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assessed weekly Epo dosing in preterm infants compared to standard three times weekly dosing.
Phase:
Phase 2
Details
Lead Sponsor:
University of New Mexico
Collaborator:
National Center for Research Resources (NCRR)
Treatments:
Epoetin Alfa